I'm LongbridgeAI, I can summarize articles.Regeneron Pharma (REGN) gained 1.54% this week to close at $746.54, outpacing the S&P 500 by about 0.39 percentage points. Trading was choppy: the stock slipped to a low of $722.02 on Monday, rebounded to $753.68 by Wednesday, then climbed back to finish Friday near the week’s upper end. The latest after-hours price sits at $746.60, roughly in line with the close.
The Week
Regeneron Pharma (REGN) gained 1.54% this week to close at $746.54, outpacing the S&P 500 by about 0.39 percentage points. Trading was choppy: the stock slipped to a low of $722.02 on Monday, rebounded to $753.68 by Wednesday, then climbed back to finish Friday near the week’s upper end. The latest after-hours price sits at $746.60, roughly in line with the close.
Key Events
The big story was Regeneron’s expanded antibody collaboration with Sanofi. The two signed a sixth amendment to their licence and collaboration agreement, with Sanofi paying $1 billion upfront and up to $7 billion in milestone payments. The same day, Regeneron announced it would present updated overall survival data from the Phase 3 C-POST study of adjuvant Libtayo in high-risk cutaneous squamous cell carcinoma at ESMO 2026; the drug had earlier received FDA fast-track designation. The US research roundup contrasted Regeneron’s FDA fast track with Alnylam’s CRL setback, underscoring the divergence within biotech innovation. The stock underperformed peers on Monday but outperformed on Wednesday’s strong trading day.
Analyst Ratings
A total of 27 brokers cover Regeneron as of the latest tally: 14 rate it buy, 4 overweight, 8 hold and 1 underweight, with no sell or no-opinion ratings. The consensus rating is buy, and the consensus target of $859.04 implies roughly 15.1% upside from the current price. Targets range from $730 to $1,030, pointing to a fairly wide spread of views. Within the biotech industry, Regeneron ranks 9th out of 508 companies, near the top of the pack.
The Week Ahead
The US CPI and core CPI prints on 14 October will set the tone for risk appetite across biotech. On the company side, Regeneron’s fiscal Q3 earnings are due before the open on 30 October, with consensus estimates at EPS $13.73 on revenue of $4.54 billion. It will also be worth watching how the expanded Sanofi pact progresses and whether the Libtayo data update at ESMO adds further detail.
In Short
Regeneron closed the week higher in choppy trade, with the Sanofi deal expansion offering a fresh capital-flow signal. Brokers remain constructive — the consensus rating is buy and the consensus target sits about 15% above spot. Valuation is in line with biotech norms at roughly 17.8x P/E and 2.4x P/B. What matters next is whether the CPI data and Q3 earnings can carry the upward momentum from the partnership news, and whether broad flows continue to rotate toward mid- and lower-profile names.
This article is generated by LongbridgeAI from market data, for information only and not investment advice.